(FBCG) Fidelity Blue Chip Growth - Ratings and Ratios
Large-Cap, Growth, Technology, Healthcare, Consumer
Dividends
| Dividend Yield | 0.04% |
| Yield on Cost 5y | 0.09% |
| Yield CAGR 5y | 58.11% |
| Payout Consistency | 73.1% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 16.8% |
| Value at Risk 5%th | 28.4% |
| Relative Tail Risk | 2.60% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.59 |
| Alpha | -6.37 |
| CAGR/Max DD | 1.27 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.313 |
| Beta | 1.344 |
| Beta Downside | 1.356 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.89% |
| Mean DD | 3.61% |
| Median DD | 1.93% |
Description: FBCG Fidelity Blue Chip Growth January 08, 2026
Fidelity® Blue Chip Growth ETF (ticker FBCG) targets at least 80 % of its net assets toward “blue-chip” U.S. equities-large- or mid-cap companies that Fidelity Management & Research deems well-known, financially robust, and positioned for above-average earnings growth. The fund’s mandate classifies it as a non-diversified large-growth ETF, meaning it concentrates holdings in a relatively small number of high-growth stocks rather than spreading across a broad market index.
As of the most recent filing (Q4 2024), the ETF carries an expense ratio of 0.35 %, below the average for actively managed large-growth funds (≈0.45 %). Its top ten holdings account for roughly 45 % of assets, with a sector tilt toward technology (≈38 % of NAV) and consumer discretionary (≈22 %). The fund’s average forward price-to-earnings multiple is about 28×, reflecting the premium investors assign to growth expectations. Recent macro drivers-namely a resilient U.S. consumer spending trend and a moderate decline in the Fed’s policy rate-have supported earnings expansion in these sectors, though a sustained rise in inflation could compress valuation multiples.
If you want a deeper, data-driven view of how FBCG’s growth exposure stacks up against alternative ETFs, ValueRay’s analytical dashboards provide granular performance and risk metrics worth exploring.
What is the price of FBCG shares?
Over the past week, the price has changed by +1.13%, over one month by +0.36%, over three months by +2.50% and over the past year by +19.66%.
Is FBCG a buy, sell or hold?
What are the forecasts/targets for the FBCG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 68.4 | 23.2% |
FBCG Fundamental Data Overview January 08, 2026
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 5.39b USD (5.39b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 5.39b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 5.39b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 10.87% (E(5.39b)/V(5.39b) * Re(10.87%) + (debt-free company))
Discount Rate = 10.87% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for FBCG ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle